Travere Therapeutics (TVTX): Valuation Check After FDA Tailwinds and FSGS Expansion Hopes for FILSPARI [Yahoo! Finance]
Travere Therapeutics, Inc. (TVTX)
Company Research
Source: Yahoo! Finance
See our latest analysis for Travere Therapeutics. Those regulatory tailwinds have lit a fire under Travere's share price, with a 1 day share price return of 13.91 percent adding to a 112.34 percent year to date share price return and a 135.14 percent 1 year total shareholder return. This suggests strong momentum rather than a one day spike. If this kind of catalyst driven move interests you, it might be worth scanning other potential winners across healthcare stocks to see what the market could be rerating next. With Travere now trading just below consensus targets but still showing a wide gap to some intrinsic value estimates, investors face a key question: is the latest FDA optimism still underpriced, or are markets already baking in the next leg of growth? Travere's most followed narrative pegs fair value slightly above the last close of $40.28, framing recent gains as only part of the upside story. The analysts have a consensus price target of $35.714 for Travere Therap
Show less
Read more
Impact Snapshot
Event Time:
TVTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TVTX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TVTX alerts
High impacting Travere Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
TVTX
News
- Why Travere Therapeutics Stock Popped by Nearly 14% on Wednesday [Yahoo! Finance]Yahoo! Finance
- Is Travere Therapeutics Still Attractively Priced After Its 135% Share Price Surge? [Yahoo! Finance]Yahoo! Finance
- Why Travere Therapeutics (TVTX) Is Up 18.9% After FDA Eases FILSPARI Oversight And Delays Adcom [Yahoo! Finance]Yahoo! Finance
- Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business Wire
- Travere Therapeutics (NASDAQ:TVTX) was downgraded by analysts at <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=TVTX&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall StMarketBeat
TVTX
Earnings
- 10/30/25 - Beat
TVTX
Analyst Actions
- 11/28/25 - HC Wainwright
TVTX
Sec Filings
- 12/16/25 - Form 4
- 12/15/25 - Form 144
- 12/3/25 - Form 4
- TVTX's page on the SEC website